Due to high overlap with ischaemic heart disease and HF, identification of DM is important in HF patients so that treatment can be individualised with, for example, GLP1 receptor agonists in eligible patients.35 Since pre-diabetes and probable DM is common in HF patients, it is reasonable to have a generous approach to glycaemic testing in HF patients. This evidence concerns the gene GLP1R and hydrops fetalis.